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CD8 cytotoxic T lymphocytes (CTLs) rely on rapid reorganization of the branched F-actin
network to drive the polarized secretion of lytic granules, initiating target cell death during
the adaptive immune response. Branched F-actin is generated by the nucleation factor
actin-related protein 2/3 (Arp2/3) complex. Patients with mutations in the actin-related
protein complex 1B (ARPC1B) subunit of Arp2/3 show combined immunodeficiency, with
symptoms of immune dysregulation, including recurrent viral infections and reduced CD8+ T
cell count. Here, we show that loss of ARPC1B led to loss of CTL cytotoxicity, with the
defect arising at 2 different levels. First, ARPC1B is required for lamellipodia formation, cell
migration, and actin reorganization across the immune synapse. Second, we found that
ARPC1B is indispensable for the maintenance of TCR, CD8, and GLUT1 membrane
proteins at the plasma membrane of CTLs, as recycling via the retromer and WASH
complexes was impaired in the absence of ARPC1B. Loss of TCR, CD8, and GLUT1 gave
rise to defects in T cell signaling and proliferation upon antigen stimulation of ARPC1B-
deficient CTLs, leading to a progressive loss of CD8+ T cells. This triggered an activation-
induced immunodeficiency of CTL activity in ARPC1B-deficient patients, which could
explain the susceptibility to severe and prolonged viral infections.
Research Article Cell biology Immunology
Find the latest version:
https://jci.me/129388/pdf
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1jci.org
Introduction
The actin cytoskeleton coordinates a wide variety of cell functions 
ranging from cell division and differentiation to migration. The 
ability to reorganize the actin network in response to both extra-
cellular and intracellular cues is pivotal for many cell types to 
perform their physiological functions (1). This is particularly 
relevant for cells of the immune system, including cytotoxic T 
lymphocytes (CTLs), which patrol the body in order to seek and 
destroy virally infected and transformed cells.
Cytolytic activity occurs upon CTL recognition of an antigen- 
presenting target cell via their TCR, which initiates the forma-
tion of a tight contact between the CTLs and target known as the 
immunological synapse (synapse). The initiation, formation, and 
maintenance of the synapse rely upon the polymerization and 
dynamic rearrangement of the cortical actin cytoskeleton (2, 3). 
Polarized secretion of granules by CTLs is intricately coordinated 
by filamentous actin depletion and recovery at the synapse, sup-
porting a central role of actin in CTL effector responses (4–6).
Cortical actin comprises a network of branched-actin fila-
ments largely nucleated by the actin-related protein 2/3 (Arp2/3) 
complex. This complex contains 7 subunits named Arp2, Arp3, 
and actin-related protein complex 1 (ARPC1), ARPC2, ARPC3, 
ARPC4, and ARPC5. Arp2 and Arp3 act as monomers from which 
new actin filaments elongate in a Y-branch orientation and recruit 
and hydrolyze ATP (7, 8). The other subunits (ARPC1–5) organize 
to form the structural core of the complex, providing an interface 
for binding to preexisting actin filaments and regulatory cofactors 
(9, 10). Optimal activity of Arp2/3 requires both the presence of 
ATP and engagement by nucleation promoting factor (NPF) pro-
teins, including Wiskott-Aldrich syndrome (WAS) protein (WASp) 
and WASp-family verprolin-homologous protein (WAVE) (11). 
WASp and WAVE are engaged in distinct signaling pathways 
downstream of TCR activation, leading to Arp2/3-mediated 
F-actin initiation and maintenance, respectively (12). Another 
member of the WASp NPF family is WASp and SCAR homologue 
(WASH), which cooperates with Arp2/3 to regulate endosomal 
protein sorting, morphology, and receptor trafficking (13–15).
The localization of NPF proteins can focus Arp2/3 activity to 
distinct compartments within the cell, e.g., plasma membrane, 
cytoplasm, endocytic vesicles, or nucleus. This can give rise to 
specialized subcellular functions for Arp2/3 within the cell (16). 
In human cells, there are 2 isoforms of the ARPC1 and ARPC5 
subunits, named ARPC1A, ARPC1B, ARPC5, and ARPC5L, 
respectively, that can be incorporated into the Arp2/3 complex, 
resulting in 4 different subfamilies. Functionally, Arp2/3 com-
plexes containing the ARPC1B/ARPC5L combination have higher 
actin nucleating activity and produce filaments that are much 
more stable than the ARPC1A/ARPC5 combination. This has 
led to the notion that Arp2/3 complex composition dictates actin 
filament dynamics and ultimately Arp2/3 intracellular func-
tions (17). Despite increasing evidence for the crucial role played 
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the contribution of Arp2/3 in CTL effector functions, we assessed 
OT-I CTL–mediated killing in the presence of either the inactive 
compound CK689 or the inhibitor CK666. Treatment with CK666 
led to a greater than 50% reduction in target cell lysis compared 
with treatment with the control compound CK689 (Figure 2A). 
We noted that CK666 treatment reduced the basal level of p-ERK 
in CTLs (Figure 2B), but made no difference to ERK phosphory-
lation triggered by TCR activation via high-dose antigen (OVA) 
or phorbol 12–myristate 13-acetate (PMA). We also found that, 
although target cell lysis was decreased upon inhibition of Arp2/3, 
we observed only a modest reduction in degranulation in response 
to OVA-loaded target cells (Figure 2, C and D). These results 
suggest a role for Arp2/3 in CTL-mediated killing that is indepen-
dent of granule release.
Arp2/3 activity controls actin remodeling at the synapse. Tar-
get cell killing involves secretion of lytic granules requiring both 
actin depletion and centrosome docking at the synapse (5, 26). 
We asked whether actin depletion and centrosome polarization 
were dis rupted when Arp2/3 was inhibited. Using quantitative 
microscopy, we evaluated the distribution of actin at the interface 
between mouse OT-I CTLs and EL4 target cells and measured 
the position of the centrosome relative to the synapse (Figure 3, 
A and B). OT-I CTL target conjugates were labeled using anti-
bodies against F-actin, γ-tubulin, and CD8 (which is expressed 
by CTLs, but not by target cells) (Figure 3A). 3D reconstructions 
of each conjugate were used to examine actin across the synapse, 
and the actin localization was quantitated as described in Meth-
ods and Supplemental Figure 1 (supplemental material available 
online with this article; https://doi.org/10.1172/JCI129388DS1). 
In CK689-treated (control) OT-I CTLs, 50% of the conjugates 
showed actin accumulated across the synapse; 30% showed 
depletion of actin across the center of the synapse, with accu-
mulation at the periphery resulting in a typical ring shape when 
visualized en face (Figure 3A and Supplemental Figure 1), and 
20% of conjugates showed an intermediate phenotype with some 
depletion from the center of the synapse (Figure 3B and Supple-
mental Figure 1). Actin depletion across the center of the synapse 
was reduced upon CK666 treatment, with only 10% of conjugates 
showing actin depletion (Figure 3B and Supplemental Figure 
1). The polarization of the centrosome toward the synapse was 
reduced upon CK666 inhibitor treatment, with 53% of conjugates 
showing the centrosome distal (>3 μm), compared with 40% after 
CK689 treatment (Figure 3B). We also examined actin dynamics 
at the synapse using live cell imaging, with OT-I CTLs expressing 
EGFP-Lifeact and the centrosome marker PACT-mRFP in the 
presence of CK689 or CK666 (Figure 3, C and D, Supplemental 
Video 1 and 2). Still images from the videos show a striking dif-
ference in the actin reorganization from first contact (0:00) in the 
presence of CK666, with reduced actin accumulation and deple-
tion (Figure 3C) compared with CK689. OT-I CTL migration was 
also affected upon Arp2/3 inhibition (Figure 3D, Supplemental 
Videos 3 and 4). Control OT-I CTLs exhibited typical lamellipodia 
that ruffled extensively in migrating cells (Supplemental Video 3). 
In contrast, OT-I CTLs treated with CK666 were devoid of lamelli-
podia, but rather displayed small membrane blebs (Supplemental 
Video 4) and reduced migratory capacity, which was reflected in 
a significantly lower speed of motility compared with that of con-
by the Arp2/3 complex in many actin-dependent processes, the 
extent of its contribution to CTL functions has yet to be defined. 
How Arp2/3 activity regulates actin reorganization and directs 
granule secretion during CTL killing is not currently known. 
The recent identification of immunodeficient patients lacking 
ARPC1B (18–22) provides an opportunity to examine the role of 
Arp2/3 in CTLs, the contribution of CTLs to the immunodeficiency, 
and the molecular basis of the disease. Although alterations in actin 
polymerization explain a number of the defects in cell motility 
and platelet secretion, many aspects of the immunodeficiency 
reported in patients with mutations in ARPC1B are poorly under-
stood, including the low CD8+ T cell counts and recurrent viral 
infections suggestive of loss of cytolytic activity.
Here, we report that Arp2/3 activity is pivotal for the cytolytic 
function of CTLs. TCR activation, degranulation, and target cell 
killing are all reduced in ARPC1B-deficient CTLs. Furthermore, 
we find that ARPC1B is required for selective receptor recycling 
to the plasma membrane via the retromer and WASH complexes. 
These include CD8 and TCR, 2 receptors critical for T cell signal-
ing, as well as GLUT1, the major glucose transporter in T cells, 
which is essential for T cell proliferation. These results provide 
a molecular explanation for the decreased CD8 count and loss 
of CTL-mediated killing giving rise to increased susceptibility to 
acute as well as the more chronic viral infections, as observed in 
ARPC1B-deficient patients.
Results
The Arp2/3 complex colocalizes with actin at the immune synapse in 
CTLs. To address the role of the ARP2/3 complex in CD8 CTLs, 
we made use of the well-characterized OT-I transgenic mouse 
model in which all T cells express the same TCR that is specific 
for the ovalbumin peptide SIINFEKL (OVA257–264) (23). To localize 
the Arp2/3 complex, we labeled OT-I CTLs before and after syn-
apse formation using an antibody against the ARPC2 subunit of 
the Arp2/3 complex (Figure 1, A and B). ARPC2 was evenly asso-
ciated with the plasma membrane in OT-I CTLs prior to conju-
gate formation, colocalizing with F-actin with a few small puncta 
within the cytoplasm. Both ARPC2 and F-actin reorganized 
upon synapse formation with target cells, accumulating at the 
edges of the synapse and depleting from the center (Figure 1A). 
Image analysis revealed a high degree of colocalization between 
ARPC2 and actin, with a Pearson’s correlation coefficient (PCC) 
of 0.75 and 0.87 in unconjugated and conjugated OT-I CTLs, 
respectively (Figure 1B). A similar analysis of Arp2/3 localization 
in OT-I CTLs transiently expressing EGFP-tagged ARPC3 and 
mApple-Lifeact also showed ARPC3 colocalized with F-actin 
both before and after synapse formation (Figure 1, C and D; PCC 
= 0.87 and 0.81, respectively). These results demonstrate the 
recruitment of Arp2/3 at the synapse, suggesting that the Arp2/3 
complex may play a role in regulating actin dynamics during 
synapse formation by CTLs.
Optimal CTL effector function relies on active Arp2/3 complex. 
The development of small compounds to inhibit Arp2/3 activity 
has provided a versatile tool to study Arp2/3-related functions in 
many cell types (24). CK666 is a reversible molecule that works by 
maintaining the complex in an inactive state, thereby preventing 
the nucleation of new actin filaments (25). To gain insights into 
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phalloidin-labeled HD hCTLs (to image F-actin) showed thick 
lamellipodia at the leading edge in cells migrating on ICAM-1–
coated surfaces, which appeared as a peripheral ring of dense, 
branched actin in hCTLs spread on anti-CD3–coated surfaces 
(Figure 4B). In contrast, ARPC1B-deficient hCTLs were devoid 
of lamellipodia, with an increased number of long filopodia-like 
projections emanating from a sparse actin network that failed to 
reorganize upon TCR activation (Figure 4B). These prominent 
filopodia were previously observed in ARPC1B-deficient neu-
trophils and platelets (18, 19) and were shown to be nucleated 
by formin activity (21). Such a shift in favor of formin-mediated 
nucleation is often noticed upon deletion of Arp2/3 compo-
nents owing to the competition between Arp2/3 and formin for 
the pool of actin monomers (27–29). Furthermore, the overall 
intensity of the phalloidin staining in hCTLs from the ARPC1B- 
trol OT-I CTLs (Figure 3D). These results suggest important roles 
for Arp2/3 during several stages leading to CTL killing, including 
cell motility, actin depletion across the synapse, and centrosome 
polarization to the synapse.
Characterization of human CTLs lacking the Arp2/3 complex 
subunit ARPC1B. We next asked whether these findings might 
also be apparent in the first ARPC1B-deficient patient that had 
been identified (18). Therefore, we differentiated human CTL 
(hCTL) expanded from a peripheral blood sample from this 
patient (see Methods). Western blot analysis of hCTL lysates 
from this patient showed a complete loss of ARPC1B together 
with an upregulation of the ARPC1A isoform when compared 
with lysates from healthy donor (HD) hCTLs (Figure 4A), in 
agreement with findings in activated T cells, EBV-transformed 
B cells, and neutrophils (22). Superresolution microscopy of 
Figure 1. Arp2/3 colocalizes with actin in migrating and synapse-forming CTLs. (A) Single confocal slices of untransfected OT-I CTLs stained with 
antibodies against CD8 (green), ARPC2 (red), and actin (magenta). (B) Left panels: merged images from A illustrating the colocalized regions in white sat-
uration after analysis. Right panels: colocalization graphs of ARPC2 voxels (red x axes) plotted against actin voxels (magenta y axes). (C) Single confocal 
slice of OT-I CTLs transfected with EGFP-ARPC3 (green) and mApple-Lifeact (magenta) constructs. (D) Left panels: merged images from C showing the 
colocalized regions in white saturation after analysis. Right panels: colocalization graphs of EGFP-ARPC3 voxels (green x axes) plotted against mApple- 
Lifeact voxels (magenta y axes). Conjugated cells were fixed 25 minutes after mixing with OVA-loaded EL4 target cells. Numbers on the graphs indicate 
the degree of colocalization expressed as a PCC. Nuclei stained with Hoechst (blue). Scale bars: 4 μm. Data representative of 2 independent experiments. 
(A) CTLs = 75; conjugates = 48. (C) CTLs = 66; conjugates = 44).
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Videos 5 and 6). HD hCTLs showed extensive actin-rich 
ruffles upon contact with target cells, resulting in actin 
accumulation 3:00 minutes after initial contact (Figure 
5C), followed by actin depletion at the synapse center 
16:00 minutes after initial contact (Figure 5C). ARP-
C1B-deficient hCTLs showed prominent filopodia, but 
neither actin accumulation nor depletion could be seen 
across the synapse (Figure 5C and Supplemental Video 6). 
Furthermore, HD hCTLs remained firmly attached to the 
target for a considerable period of time (26 minutes) (Sup-
plemental Video 5), whereas ARPC1B-deficient hCTLs 
failed to do so within the same period of time. Taken 
together, these observations suggest that ARPC1B expres-
sion is required for Arp2/3-mediated actin remodeling at 
the synapse in hCTLs.
Pleiotropic defects in ARPC1B-deficient hCTLs. Our 
results using the mouse OT-I system suggest that opti-
mal killing of target cells requires Arp2/3 activity (Figure 
2). Hence, we sought to examine the impact of ARPC1B 
deficiency on the effector functions of hCTLs. Previous 
work has shown that the presence of IL-2 during in vitro 
culturing of hCTLs or NK cells can restore cytotoxicity in 
hCTLs from familial hemophagocytic lymphohistiocytis 5 
(FHL5, due to STXBP2 defect) or WAS patients (32–34). 
We therefore tested cytotoxicity and degranulation using 
hCTLs either cultured in IL-2 continuously or deprived of 
IL-2 for 16 hours prior to the lysis assay. Measuring LDH 
release during target cell lysis showed reduced cytotoxic-
ity from ARPC1B-deficient hCTLs (20%) compared with 
HD hCTLs (58%, Figure 6A). Removal of IL-2 reduced 
cytotoxicity further for both HD and ARPC1B-deficient 
hCTLs (Figure 6B). Using the IncuCyte system to monitor loss 
of target cells over a longer time scale after IL-2 deprivation, 
it was clear that ARPC1B-deficient hCTLs failed to kill target 
cells, while HD hCTLs killed increasing numbers of targets over 
time (Figure 6C).
Western blot analysis of ERK phosphorylation in hCTLs 
showed reduced p-ERK in ARPC1B-deficient compared with 
HD hCTLs both under basal conditions and following TCR acti-
vation with 2 different concentrations of anti-CD3 (Figure 6D). 
Consistent with the reduced cytotoxicity and TCR signaling, 
upon target cell challenge, ARPC1B-deficient hCTLs showed 
a reduced mean percentage degranulation (56%) compared 
with HD hCTLs (71%, Figure 6, E and F). Upon IL-2 deprivation 
for 16 hours, degranulation was diminished in both HD (63%) 
and ARPC1B-deficient (40%) hCTLs in line with the reduced 
target cell lysis seen without IL-2 (Figure 6, E and F). Further-
more, granzyme B protein expression, which is known to be IL-2 
dependent (35, 36), was also reduced in the absence of IL-2 with 
ARPC1B-deficient hCTLs compared with HD hCTLs (Figure 6G). 
Of note, the higher expression of ARPC1A isoform observed in 
ARPC1B-deficient hCTLs (Figure 4A and Figure 6H) was 
decreased in the absence of IL-2. In summary, we found that loss 
of ARPC1B was accompanied by reduced TCR signaling, degran-
ulation, granzyme B expression, and cytotoxicity in hCTLs. These 
results suggest that IL-2 regulates a plethora of signaling path-
ways that control gene transcription, protein synthesis, and the 
deficient patient was decreased relative to HD hCTLs, indicat-
ing a defect in actin polymerization following stimulation (Fig-
ure 4C). These results show that, despite the upregulation of 
ARPC1A, the loss of ARPC1B results in a disruption of the actin 
cytoskeleton in hCTLs, suggesting a critical role of ARPC1B in 
the activity of the Arp2/3 complex in hCTLs.
ARPC1B-deficient hCTLs have modified and unstable immune 
synapses. The immunological synapse formed between CTLs and 
target cells involves extensive remodeling of the cortical actin 
cytoskeleton (30, 31). Given the defects in actin reorganization 
we had observed, we examined synapses formed by ARPC1B- 
deficient hCTLs with target cells by electron microscopy (Fig-
ure 5A). Many interdigitations were evident during early con-
tact between HD hCTLs and target cells. By contrast, ARPC1B- 
deficient hCTL synapses were devoid of interdigitations, with 
membranes appearing more flattened. These differences were 
also apparent from immunofluorescence imaging of hCTLs 
labeled with antibodies against ARPC1B and phalloidin (which 
labels F-actin). ARPC1B-deficient hCTLs showed loss of ARP-
C1B and a reduced signal for actin with no actin accumulation 
at the synapse, while HD hCTLs showed strong signals for both 
actin and ARPC1B with an accumulation of actin at the synapse 
(Figure 5B). Live cell imaging of HD and ARPC1B-deficient 
hCTLs transduced with lentivirus expressing the F-actin probe 
mApple-Lifeact further illustrated the striking differences 
between the HD and the patient cells (Figure 5C, Supplemental 
Figure 2. Arp2/3 inhibition affects CTL killing. (A) Killing capacity of OT-I CTLs 
treated with the inactive control compound CK689 or the Arp2/3 inhibitor CK666, 
expressed as a percentage of target cell lysis at the effector-to-target (E:T) ratios 
indicated (mean of 3 independent experiments; error bars indicate SEM). (B) 
Western blot of p-ERK1/2 and total ERK1/2 in nonstimulated (NS) cells or following 
stimulation with 1 μM OVA peptide or 50 nM PMA (for 15 minutes) in control versus 
treated cells (representative of 3 independent experiments). Numbers indicate the 
fold change (ratio) of p-ERK1 expression following stimulation and after normaliza-
tion to total ERK1 expression. (C) Representative flow cytometry plot and quantita-
tion (D) of LAMP1-PE (CD107a) uptake in OT-I CTLs in the absence (blue) or presence 
(red) of OVA-loaded EL4 (gated on CD8+ cells) after 3 hours following treatment with 
CK689 or CK666 (n = 3 independent experiments in duplicate).
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formed by ARPC1B-deficient hCTLs displayed an intermediate 
phenotype (Supplemental Figure 1, A and B, and Supplemental 
Figure 2A) and no conjugates formed a ring-like structure. Label-
ing conjugates with antibodies to CD8 and γ-tubulin allowed us 
to monitor centrosome polarization to the synapse. While 50% 
of HD hCTL conjugates polarized the centrosome to within 3 μm 
of the synapse, only 32% of ARPC1B-deficient hCTLs showed 
centrosome polarization to less than 3 μm of the synapse, demon-
strating a reduction in the efficiency of centrosome polarization, 
potentially linked to reduced TCR signaling (Supplemental Fig-
ure 2B and ref. 38). Finally, we asked whether the secretory gran-
ules polarized to the synapse in the absence of ARPC1B by stain-
ing tubulin to visualize microtubules and by using antibody to 
LAMP1 to label the secretory granules (Supplemental Figure 2C). 
cytoskeleton (37), may provide partial compensation for the loss 
of effector function in ARPC1B-deficient hCTLs by upregulating 
the expression of an alternative ARPC1 isoform as well as gran-
zyme B, a cytolytic protein required for in vivo antiviral immunity.
ARPC1B deficiency impairs the polarization of cytotoxic 
machinery to the synapse. As ARPC1B-deficient hCTLs displayed 
a marked killing defect associated with reduced TCR signaling 
and granule secretion, we asked whether the cytotoxic machinery 
polarized to the synapse in these cells. Quantitation of 3D imag-
es of fixed hCTL-target conjugates, stained for CD8 to identify 
hCTLs and the actin cytoskeleton (Supplemental Figure 2), 
showed that, while HD hCTLs were able to reorganize the actin 
cytoskeleton across the synapse (41%), showing either interme-
diate (22%) or ring-like phenotype (19%), only 10% of conjugates 
Figure 3. Arp2/3 inhibition impairs actin dynamics in CTLs. (A) Confocal projections of OT-I CTLs treated with 90 μM of CK689 or CK666 mixed with 
OVA-loaded EL4 for 25 minutes; cells were fixed and labeled with antibodies against CD8 (green), actin (red), and γ-tubulin (white) to mark the centrosome 
(white arrows). A representative 3D reconstruction of en face interaction (white box) of the actin phenotype at the interface between the OT-I CTLs and 
its target. Scale bars: 5 μm. (B) Quantitation derived from images as exemplified in A and showing the percentages of conjugates displaying the different 
actin reorganization phenotypes at the synapse (left panel, see Supplemental Figure 1) or the centrosome distance relative to the synapse (right panel: 
CK689 CTLs = 190, conjugates = 91, CK666 CTLs = 179, conjugates = 80, mean of 3 independent experiments, error bars indicate SEM). (C) Actin dynamics 
and centrosome position (white arrows) in OT-I CTLs expressing EGFP-Lifeact (green) and PACT-mRFP (red) during interaction with EL4 blue at various 
time point (min:s) from the first contact. Images are confocal projections from Supplemental Videos 1 and 2. Scale bars: 5 μm. (D) OT-I CTL motility while 
migrating on ICAM-1 following treatment with 90 μM CK666 or CK689. The speeds of cell migration were analyzed with time-lapse images (see Methods). 
The graph includes plots of 28 cells for CK689 and 18 cells for CK666 from 3 videos each. ***P < 0.0001, unpaired t test.
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hCTLs were distinguished from target cells by the human-specific 
LAMP1 antibody, which does not recognize mouse target cells. 
No obvious differences were noted in the microtubule cytoskel-
eton of HD and ARPC1B-deficient hCTLs. However, polariza-
tion of the granules was impaired in ARPC1B-deficient hCTLs, 
with less than 10% of hCTLs showing granule polarization, while 
more than 40% of HD hCTLs showed polarized granules forming 
a bright cluster at the contact site between hCTLs and target cells 
(Supplemental Figure 2C). Hence, although ARPC1B-deficient 
hCTLs were able to secrete granules, not all granules clustered 
at the synapse. Thus, loss of ARPC1B not only disrupts actin re or-
ganization across the synapse, but also impairs the polarization 
of the centrosome and the cytotoxic machinery to the synapse, 
weakening the overall effector function of CTLs.
Reduced cell surface TCR-αβ, CD8, and GLUT1 in ARP-
CB1B-deficient hCTLs. In order to culture hCTLs from HD and the 
ARPC1B-deficient patient, we purified CD8+ T cells using nega-
tive selection, depleting with antibodies against markers for CD4+ 
T cells, B cells, NK cells, monocytes, granulocytes, and dendritic 
cells (see Methods). While purified HD T cells were 99% CD8 
positive 13 days after stimulation, only 17% of the purified 
ARPC1B-deficient T cells expressed cell surface CD8 detected by 
flow cytometry, with 79% of the T cells in the population express-
ing neither CD8 nor CD4 (Supplemental Figure 3A). The median 
fluorescence intensities (MFI) for CD3 and CD8 were comparable 
in patient and HD, indicating that the number of CD8 cells in the 
population was specifically reduced (Supplemental Figure 3B). 
When we examined TCR-αβ expression, we also noticed a marked 
reduction in the number of ARPC1B-deficient cells expressing 
both TCR-αβ and CD8 compared with HD cells, 13% and 96%, 
respectively (Supplemental Figure 3C). However, the MFI of TCR-
αβ staining in the ARPC1B-deficient cells that retained TCR-αβ 
and CD8 expression was not significantly reduced relative to that 
of their HD counterparts (Supplemental Figure 3D). No expression 
of TCR-γδ receptor was seen (data not shown). Immunofluores-
cence microscopy analysis showed CD8 was readily detected on 
the plasma membrane of HD cells, but only weakly on the plasma 
membrane of ARPC1B-deficient cells (Figure 7A). However, we 
noted that up to 10% of ARPC1B-deficient patient cells with no 
apparent CD8 on the plasma membrane showed intracellular 
puncta of CD8 (Figure 7B); furthermore, we observed perforin 
expression within cells lacking plasma membrane CD8 (Supple-
mental Figure 3F). These results suggested that these cells were 
CTLs that no longer expressed cell surface CD8. Therefore, we 
asked whether receptor recycling might be impaired in ARPC1B- 
deficient hCTLs.
Although Arp2/3 is perhaps best known for its role in modeling 
the cortical actin cytoskeleton, it has also been shown to have a role 
in the regulation of endocytosis and receptor recycling via the ret-
romer and WASH complexes (39, 40). Therefore, we asked whether 
these pathways were affected in ARPC1B-deficient hCTLs. Label-
ing with antibodies against the retromer subunit VPS35 as well as 
FAM21, the subunit of the NPF WASH complex that interacts with 
the retromer (41–43), showed the proteins colocalized on intracellu-
lar vesicles in both HD and ARPC1B–deficient hCTLs and demon-
strated that the retromer-dependent recycling machinery was not 
only present, but also correctly localized in both (Supplemental 
Figure 3G). Next, we asked whether the localization of GLUT1, a 
well-established cargo protein of the retromer recycling pathway 
(44, 45), was affected in ARPC1B-deficient hCTLs. We found that, 
although GLUT1 could be seen both on the plasma membrane 
and intracellularly in HD hCTLs, GLUT1 was not detected on the 
plasma membrane of ARPC1B-deficient hCTLs (Figure 7, C and 
D), resulting in a reduced GLUT1 intensity in ARPC1B-deficient 
Figure 4. Differential actin structure in hCTLs from ARPC1B-deficient patient. (A) Immunoblot analysis of calnexin, ARPC1B, and ARPC1A in hCTL lysates 
from 4 different HD (lanes 1 to 4) and ARPC1B patient samples from day 20 (lanes 4 to 6) and day 12 (lanes 7 and 8) after expansion. HD 4 (lanes 4 and 7) 
was used for the rest of the study. MW markers in kD. Lanes were run on the same gel, but were noncontiguous. (B) Single plane of a Z-stack across hCTLs 
from HD or ARPC1B patient plated on ICAM-1– (0.5 μg/mL) or anti-CD3–coated (10 μg/mL; right panel) slide, fixed, stained with phalloidin and CD8 (not 
shown), and imaged using Structural Illumination Microscopy. Scale bars: 3 μm. (C) Quantitation of the mean intensity of phalloidin staining (F-actin) in 
HD or ARPC1B-deficient patient hCTLs generated from images as exemplified in B (right panel) (see Methods for description). HD n = 10 cells ARPC1B- 
patient n = 13 cells. ***P = 0.0053, unpaired t test. Data representative of 3 independent experiments.
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hCTLs compared with HD (Figure 7, C–E). GLUT1 was only 
observed as an intracellular pool colocalizing with the endosomal 
marker EEA1 in ARPC1B-deficient hCTLs (Figure 7, D and E). We 
were also able to reproduce these findings in a second ARPC1B- 
deficient patient (Supplemental Figure 4). These results demon-
strate that ARPC1B is required for retromer and WASH complex–
mediated recycling, as GLUT1 is lost from the plasma membrane 
in ARPC1B-deficient hCTLs. Furthermore, our results suggest 
that TCR-αβ and CD8 also require retromer and WASH complex– 
mediated recycling to maintain cell surface levels in CTLs.
As GLUT1 is the major glucose transporter for hCTLs, required 
for cell metabolism and proliferation (46), we asked whether cell 
proliferation was affected by analyzing division of hCTLs over 5 
days. While the majority of HD hCTLs underwent multiple divi-
sions following stimulation with plate-bound anti-CD3, fewer ARP-
C1B-deficient hCTLs divided less frequently, revealing a defect in 
proliferation of ARPC1B-deficient hCTLs compared with HD (Fig-
ure 7F). We followed the fate of hCTLs derived from the ARPC1B- 
deficient patient after successive stimulations (see Methods and 
Supplemental Figure 5A). Although there was a comparable CD4/
CD8 ratio in patient and HD PBMC initially, we observed a pro-
gressive decrease in the ARPC1B-deficient CD8+ population with 
successive stimulations (Supplemental Figure 5B). Stimulation 
of a CD8-purified population triggered a greater decrease in the 
percentage of CD8+ T cells in a ARPC1B-deficient patient compared 
with HD (Supplemental Figure 5, D and E). These results demon-
Figure 5. Electron and light microscopy reveal atypical synapse formation by ARPC1B-deficient hCTLs. (A) Electron micrograph of HD and ARPC1B 
patient hCTLs conjugated to P815 target cells (false colored in blue) for 25 minutes. (B) hCTLs from HD and ARPC1B-deficient patient were conjugated to 
blue P815 target cells, fixed, and labeled with anti-CD8 (green) and anti-ARPC1B (red) antibodies and phalloidin (white). 3D reconstructions of Z-stack are 
shown. Scale bars: 3 μm. Data are representative of 3 independent experiments (A and B). (C) Actin dynamics in HD and ARPC1B-deficient patient hCTLs 
expressing mApple-Lifeact (red) during interaction with blue P815 target cells. Images are single confocal slice from Video 3 at the indicated time points 
(min:s) from the first contact. Data are representative of 5 independent experiments. Scale bars: 5 μm.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
8 jci.org
Discussion
T and NK cell activation lead to a rapid reorganization of F-actin 
across the synapse, coordinating receptor signaling platforms and 
intracellular effectors to deliver an appropriate immune response 
(2, 48–50). Recent studies have begun to probe the role of the 
Arp2/3 complex in actin nucleation in T cells (51–53). The ARPC1 
subunit is thought to play a regulatory role within the Arp2/3 com-
plex, forming an interface together with ARPC5 and Arp2 that is 
critical for actin nucleation (54–56). Although deletions of many 
subunits of the Arp2/3 complex are embryonic lethal (57), deletion 
of ARPC1B is not, as it is predominantly expressed in the hemo-
poietic lineage (18), where ARPC1A expression is minimal. Patients 
lacking ARPC1B show combined immunodeficiency arising from 
loss of ARPC1B in different hemopoietic cells (18–22). Clinical pre-
sentations reported for these patients include platelet defects, mild 
thrombocytopenia, recurrent viral and bacterial infections, ecze-
ma, and enterocolitis, with different combinations of these defects 
varying among patients. Studies on ARPC1B-deficient T cells have 
described reduced proliferation in response to anti-CD3 and vari-
able or reduced CD8+ T cell counts in the blood (21, 22). Further-
more, defects in actin accumulation at the synapse and during T 
cell migration have also been described (21). However, the molec-
ular basis of the decreased proliferation and reduced CD8 popula-
tion have remained elusive and whether CD8-mediated cytotoxic-
ity was affected by loss of ARPC1B is not known.
Here, we show that absence of ARPC1B leads to a loss of CTL/
CD8 cytotoxicity, with the defect arising at 2 different levels. First, 
ARPC1B is essential for the polymerization of actin in lamellipo-
dia, required for cell motility and synapse formation. However, in 
addition, activation induces a decrease in the CD8+ cell population 
arising from the role of ARPC1B in retromer and WASH complex–
mediated recycling of key surface receptors required for T cell 
activation (TCR and CD8) and proliferation (GLUT1).
We used 2 different approaches to examine the role of Arp2/3 
in CTL-mediated cytotoxicity. First, using drug treatment on OT-I 
CTLs, we found that inhibition of Arp2/3 acted at several stages 
during CTL killing: we found that lamellipodia formation and the 
speed of migration were both inhibited upon CK666 treatment, as 
was the reorganization of actin across the synapse and the polar-
ization of the centrosome that directs granules and the lethal hit. 
Cytotoxicity was reduced, with a modest reduction in degranula-
tion, while TCR-mediated p-ERK activation was unaffected. Thus, 
the decreased target cell killing observed in these short-term 
cytotoxicity assays (1.5 hours) was most likely linked to defective 
lamellipodia formation during migration and subsequent synapse 
maintenance rather than a substantial signaling defect, consistent 
with recently published observations (58). Second, we observed a 
cytotoxicity defect in patient-derived ARPC1B-deficient hCTLs. 
However, in addition to impaired lamellipodia formation, sub-
stantial decreases in TCR signaling and degranulation were also 
observed, suggestive of a more profound role for Arp2/3 in CTLs 
beyond those observed in the short-term inhibitor assay.
In the absence of ARPC1B, we saw an upregulation of the 
nonhematopoietic isoform of ARPC1A, which was enhanced 
in the presence of IL-2. However, upregulation of ARPC1A did 
not prevent the loss of cytotoxicity observed in the ARPC1B- 
deficient patient, suggesting only weak compensation by ARPC1A 
strate the importance of ARPC1B in CTLs upon selection and pro-
liferation. When ARPC1B was absent, GLUT1, the main glucose 
transporter in CTLs (47), together with TCR-αβ and CD8, was lost 
from the plasma membrane with profound consequences for CD8 
CTL maintenance.
Figure 6. Absence of ARPC1B affects CTL effector functions. (A and B) 
Percentage lysis of P815 (after 2 hours) by HD or ARPC1B-deficient patient 
hCTLs at the indicated effector-to-target ratios in the presence (A) or 
absence (B) of IL-2. (C) Percentage lysis of P815-NucLight Red targets over 
time measured by IncuCyte killing assay using HD or ARPC1B-deficient 
patient hCTLs that have been deprived of IL-2 for 16 hours. (D) Western blot 
analysis of p-ERK1/2 and ERK1/2 expression in HD and ARPC1B- 
deficient patient hCTLs stimulated for 15 minutes with plate-bound anti-
CD3 antibody at the indicated concentrations. Numbers indicate the fold 
change (ratio) of p-ERK2 expression following stimulation in ARPC1B- 
deficient patient and HD after normalization to total ERK2 expression. 
(E) Representative flow cytometry plot and quantitation (F) of LAMP1-PE 
(CD107a) uptake in HD and ARPC1B-deficient patient hCTLs (gated on CD8+ 
cells) after 2 hours incubation under the indicated conditions. (G and H) 
Immunoblot of granzyme B (G) and ARPC1A (H) in HD and ARPC1B- 
deficient patient in the presence or absence of IL-2. MW markers in kD. (A–C) 
Data are shown as mean of 3 independent experiments; error bars represent 
SEM. (D, G, H) Data are representative of 4 independent experiments.
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increasing degranulation in both control and patient (22). In con-
trast to Arp2/3 inhibitor assays on OT-I CTLs, purified CD8 cells 
derived from the ARPC1B-deficient patient showed reduced TCR 
signaling together with reduced degranulation and cytotoxicity 
or a nonredundant role of ARPC1B in CTLs. Similarly, a lack of 
complementation has been observed in ARPC1B–deficient plate-
lets with upregulated ARPC1A (19). A defect in NK cell degranu-
lation in ARPC1B-deficient patients has been reported, with IL-2 
Figure 7. Absence of ARPC1B alters surface expression of CD8 and GLUT1 in hCTLs. (A–D) HD and ARPC1B-deficient patient hCTLs were fixed in PFA for 20 
minutes, permeabilized, and stained with an antibody against CD8 alone (green) (A and B) or in combination with anti-GLUT1 (red) and anti-EEA1 (white) 
antibodies (C and D). Images are 3D reconstructions of Z-stack. Scale bars: 4 μm. (E) Measurement of the mean intensity of GLUT1 expressed in AU and 
the degree of colocalization with EEA1 expressed as PCC (see Methods) in HD and ARPC1B-deficient patient hCTLs based on images as sampled in C and 
D. HD, n = 41 cells; ARPC1B-deficient patient, n = 38 cells. P < 0.005 (unpaired t test). **P < 0.0013; ***P < 0.0002. (F) Flow cytometry analysis of the 
proliferation capacity of HD and ARPC1B-deficient patient hCTLs (gated on live CD8+ cells) in the absence (blue) or presence (red) of plate-bound anti-CD3 
stimulation (1 μg/mL). All data are representative of 3 independent experiments.
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In conclusion, we find that the ARPC1B subunit of the Arp2/3 
complex is essential for CTL cytotoxicity, acting not only by regu-
lating actin reorganization at the synapse, but also by controlling 
the cell surface levels of TCR, CD8, and GLUT1 via its role in ret-
romer and WASH-mediated recycling. Our study indicates that 
mutations in ARPC1B will trigger progressive CTL activation–
induced immunodeficiency and provides mechanistic insights 
into the immune dysregulation observed in this disease.
Methods
Antibodies and reagents. The following primary antibodies were used: 
rat anti-mouse CD8 (clone YTS105, gift from Herman Waldmann, Uni-
versity of Oxford, Oxford, United Kingdom), rabbit anti-human LAMP1 
(AS120) (76), mouse anti-tubulin (TAT-1, gift of Keith Gull, University 
of Oxford, Oxford, United Kingdom), mouse anti-γTubulin (clone 
GTU-88, T6557, MilliporeSigma), rabbit anti-γTubulin (T5192, Milli-
poreSigma), mouse anti–β-actin (clone AC-15, A5441, MilliporeSigma), 
mouse anti-actin (clone AC-40, catalog A3853, MilliporeSigma), rabbit 
anti–F-actin (catalog A2066, MilliporeSigma), rabbit anti-ARPC2 (cat-
alog 07-227, MilliporeSigma), rabbit anti–p-ERK1/2 (clone D13.14.4E, 
4370S, Cell Signaling), mouse anti-ERK1/2 (clone L34F12, 4696S, Cell 
Signaling), rabbit anti-ARPC1B (catalog HPA004832, MilliporeSigma), 
rabbit anti-ARPC1A (catalog HPA004334, MilliporeSigma), rabbit 
anti-calnexin (catalog C4731, MilliporeSigma), mouse anti–granzyme 
B (clone 2C5/F5, catalog 550558, BD Biosciences — Pharmingen), 
rabbit anti-GLUT1 (catalog ab15309, Abcam), mouse anti-VPS35 
(clone B5, catalog SC374372, Santa Cruz Biotechnology Inc.), rabbit 
anti-FAM21 (catalog ABT79, EMD Millipore), mouse anti-EEA1 (clone 
14-EEA1, catalog 610456, BD Biosciences), and mouse anti-human 
CD8α–Alexa Fluor 488 (clone 37006, catalog FAB 1509G, R&D Sys-
tems). The following secondary antibodies from Thermo Fisher were 
used: Alexa Fluor 488 goat anti-mouse IgG (catalog A11029), Alexa 
Fluor 488 goat anti-rat IgG (catalog A11006), Alexa Fluor 555 goat 
anti-rabbit IgG (catalog A21429), Alexa Fluor 647 goat anti-mouse IgG 
(catalog A21236), Alexa Fluor 633 goat anti-rabbit (catalog A21071). 
Additional reagents used were as follows: phalloidin Alexa Fluor 555 
(catalog A34055, Thermo Fisher) or Alexa Fluor 647 (catalog A22287, 
Thermo Fisher), CK666 (catalog ab1412131, Abcam), and CK689 
(182517, catalog EMD Millipore).
Primary cell culture. Spleens collected from C57BL/6 OT-I Rag1-/- 
mice were homogenized through a 70 μm filter. Splenocytes from 
OT-I mice were stimulated with 10 nM of OVA257–264 [SIINFEKL] pep-
tide (AnaSpec) and cultured for 3 days to generate OT-I CTLs. OT-I 
CTLs were maintained for 8 to 10 days in mouse T cell media consist-
ing of RPMI 1640 medium (Thermo Fisher) supplemented with 10% 
(v/v) FBS (Labtech), ≥100 U/mL recombinant murine IL-2 (212-12, 
PreproTech), 50 μM β-mercaptoethanol (Thermo Fisher), 100 U/ml 
penicillin-streptomycin (MilliporeSigma), 2 mM l-glutamine (Milli-
poreSigma), and 1 mM sodium pyruvate (Thermo Fisher).
PHA blasts from frozen human PBMCs isolated from HD or 
ARPC1B-deficient patients carrying a homozygous mutation, 
c.491_495delinsCCTGCCC on exon 7 (18) or mutation c.897_910delC-
GAGCGCTTCCAGA on exon 10 (22), were stimulated with 106 cells/
mL of γ-irradiated (30 Gy using a Gammacell 1000 Irradiator) PBMCs 
and 1 μg/mL PHA (MilliporeSigma) and grown in human T cell media 
composed of the following: RPMI 1640 supplemented with 5% (v/v) 
human serum (H6914, MilliporeSigma), 2% (v/v) recombinant IL-2 
compared with the HD population. Starting with purified CD8 
cells, after TCR stimulation, which is required to maintain hCTL 
population in vitro, we found a reduction in patient cells express-
ing both TCR-αβ and CD8. Loss of TCR-αβ and CD8 on the 
plasma membrane in ARPC1B-deficient hCTLs could account for 
the decreased TCR activation–induced p-ERK signaling and con-
tribute to the reduced cytotoxicity that we observed.
It is well documented that activation of the TCR leads to 
its rapid internalization and recycling back to the plasma mem-
brane is required for maintaining surface levels of TCR (59–62). 
We noted that CD8 could be seen within ARPC1B-deficient 
cells, but not on the plasma membrane, suggesting that CD8 
follows the same fate as TCR. Furthermore, patient cells that 
had lost CD8 were found to express the cytolytic protein perfo-
rin, confirming that these cells were CTLs. Therefore, Arp2/3 
is essential for the maintenance of CD8 and TCR on the cell 
surface. Arp2/3 plays a key role in generating actin patches on 
endosomes that facilitate the transport of selected transmem-
brane proteins back to the plasma membrane via the retromer 
and WASH complex recycling pathway (13, 15, 63). We found 
that GLUT1, a well-characterized cargo protein of the retromer/
WASH pathway (15, 44, 64, 65), was also lost from the plasma 
membrane in ARPC1B-deficient hCTLs; this was not associated 
with abnormal endosomes morphology as observed in the 
absence of WASH complex (66). Moreover, ARPC1B-deficient 
patients do not exhibit symptoms of spastic paraplegia or Par-
kinson’s disease, due to mutation in the strumpellin subunit of 
the WASH complex and mutation in the VPS35 subunit of the 
retromer complex, respectively (67–69). Therefore, the loss of 
ARPC1B does not affect the retromer and WASH machinery per 
se, but rather the F-actin–dependant endosome–to–cell surface 
recycling that relies on Arp2/3 activity (70). As GLUT1 is a key 
nutrient transporter required for T cell activation (71, 72), prolif-
eration (46), and effector functions (73, 74), loss of GLUT1 could 
account for the impaired proliferation we observed in our exper-
iments. We propose that loss of surface GLUT1 would likely 
contribute to the CD8 lymphopenia in the ARPC1B-deficient 
patient. Our results emphasize the importance of retromer- 
mediated recycling in the maintenance of TCR, CD8, and 
GLUT1 on the cell surface of CTLs.
Based on our findings, we propose that ARPC1B deficiency 
results in (a) the loss of lamellipodial contact, which is pivotal for 
synapse maintenance and CTL secretion; and (b) a reduction of 
TCR, CD8, and GLUT1 on the plasma membrane; these 3 recep-
tors are essential for TCR activation, effector function, and pro-
liferation in CTLs. As receptor recycling is triggered upon TCR 
activation (62, 75), the loss of these 3 receptors is exacerbated 
upon (re)activation. Thus, each repeated challenge will result 
in a relative decrease in the specific CTL/CD8 population and 
a reduced ability to respond, driving the susceptibility to viral 
disease (22). The lack of properly induced and sustained CD8+ T 
cell activity in ARPC1B deficiency may underlie the severe acute 
and prolonged viral infections observed in many of the patients, 
being either systemic (CMV and EBV infections) or localized 
(including respiratory syncytial virus [RSV] bronchiolitis, and 
adenovirus pneumonitis as well as HPV and molluscum conta-
giosa virus [MCV] skin infections) (22).
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which was also added to the killing assay media. For experiments 
without IL-2, hCTLs were washed and cultured in media without 
IL-2 for 16 hours prior to the assay. After 1.5 hours to 2 hours incu-
bation, the percentage of target cell lysis was determined using the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay following the man-
ufacturer’s instructions (Promega).
IncuCyte killing assay. Flat bottom 96-well plates (3595, Corning) 
were coated with 50 μL/well Poly-l-ornithine (PLO) (P4957, Milli-
poreSigma) for 1 hour at room temperature (RT) and subsequently dried 
for 1 hour at RT. P815-NucLight Red (2500 cells) were seeded per well 
in phenol red–free human T cell media without IL-2 and left to attach 
to the plate overnight at 37°C. Additionally, hCTLs (day 11 after stim-
ulation) were cultured in human T cell media without IL-2 overnight 
at 37°C. The following day, hCTLs were added to the P815-NucLight 
Red target cells in the presence or absence of 0.5 μg/mL anti-CD3 anti-
body (clone UCHT1, catalog 555330, BD Biosciences — Pharmingen) 
at an effector-to-target ratio of 8:1. Loss of red fluorescence (i.e., tar-
geted cell death) was monitored every 30 minutes for 8 hours using the 
IncuCyte S3 live-cell analysis system (Essen Bioscience) and plotted as 
percentage of lysis.
Flow cytometry. Degranulation assays were carried out as previ-
ously described (78) with the exception of hCTLs being washed and 
maintained in media without IL-2 (for 16 hours) where indicated. 
Briefly, OT-I CTLs (day 7 after stimulation) or hCTLs (day 12 after 
stimulation) were mixed at a 1:1 ratio with their respective target cells 
and incubated for 2 to 3 hours at 37°C in the presence of rat anti-mouse 
CD107a-PE (clone 1D-4B, catalog 12-1071-83, eBioscience) or mouse 
anti-human CD107a-PE (clone H4A3, catalog 328608, BioLegend) 
and in the case of hCTLs, anti-CD3 antibody (clone UCHT1, catalog 
555330, BD Biosciences). Where indicated, CK689 or CK666 was 
added in the media at 90 μM. CTLs were stained with either rat anti-
mouse CD8a-APC (clone 53-6.7, catalog 100712, BioLegend) or mouse 
anti-human CD8-APC (clone MEM-31, catalog 26004, Abcam). For 
surface staining of transmembrane receptors, hCTLs at day 13 after 
stimulation were washed in FACS buffer (D-PBS + 1% FBS), resus-
pended at 0.5 × 106 cells/mL, and costained for 30 minutes at 4°C 
with mouse anti-human CD3-PE (clone UCHT1, catalog 12-0038-42, 
eBiosciences), mouse anti-human CD8-FITC (clone UCHT-4, cat-
alog F-0772, MilliporeSigma), mouse anti-human CD4-APC (clone 
RPA-T4, catalog 17-0049-42, Thermo Fisher), or mouse anti-human 
TCR-αβ–APC (clone IP26, catalog 17-9986-42, eBioscience). The iso-
type control antibodies used were mouse IgG1-PE (catalog ab81200, 
Abcam), mouse IgG2A-FITC (catalog ab81197, Abcam), and mouse 
IgG1κ-APC (catalog 17-4714-82, eBioscience). Cells were washed, 
resuspended in FACS buffer, and acquired on a BD Accuri C6 Flow 
Cytometer (BD Biosciences). For analysis of CD4/CD8 ratios, samples 
were washed in PBS, resuspended at 106 cells/mL, and costained with 
mouse anti-human BUV395 (clone G42-8, catalog 743070, BD Bio-
sciences), mouse anti-human CD3-BV711 (clone SK7, catalog 344837, 
BioLegend), rat anti-human CD4-PE (clone A161A1, catalog 357404, 
BioLegend), and a Live/Dead fixable NIR (catalog 423105, Thermo 
Fisher) for 25 minutes on ice. Unbound antibodies were removed by 
washing cells in PBS, 1% FCS; samples were fixed in 4% PFA for 10 
minutes and resuspended in PBS prior to acquisition on a LSR Fortessa 
Flow Cytometer (BD Biosciences). All samples were gated on forward 
and side scatter and for singlets, and 20,000 single cells (for surface 
staining assay), 100,000 single cells (for CD4:CD8 ratio experiment), 
(≥100U/mL; produced from IL-2–expressing X63 myeloma cells), 50 
μM β-mercaptoethanol, 0.075% sodium bicarbonate (Thermo Fish-
er), 2mM l-glutamine, and 1 mM sodium pyruvate. CD8+ cells were 
purified by negative selection at day 10 after stimulation using the 
Dynabeads Untouched Human CD8 T cells Isolation Kit, depleting 
CD4, CD14, CD16a, CD16b, CD19, CD36, CD56, CD123, and CD235a 
(Thermo Fisher). hCTLs were restimulated every 3 weeks with irradi-
ated PBMCs and 1 μg/mL PHA as described earlier.
Cell line culture. To generate P815-NucLight Red, P815 was trans-
duced with the IncuCyte NucLight Red Lentivirus (4625, Essen Bio-
science) to stably label the nuclei with mKate2 red fluorescent pro-
tein. After 3 days, successfully transduced cells were sorted by FACS 
(Becton Dickinson Influx Cell Sorter). Subsequently, P815-NucLight 
Red cells were kept under continuous selection conditions with 
media containing 1 μg/mL puromycin (Thermo Fisher). HEK293T, 
EL4, EL4-Farnesyl-5-TagBFP2 (blue EL4) (5), P815-FARN-TagB-
FP2 (blue P815), and P815 target cells were maintained in DMEM 
medium (Thermo Fisher) containing 10% FBS and 100 U/mL of 
penicillin-streptomycin.
Cloning and expression of lentiviral mApple-Lifeact and ARPC3 
nucleofection. The plasmid mApple-Lifeact-7, a gift from Michael 
Davidson (Florida State University, Tallahassee, Florida, USA) 
(Addgene plasmid 54747), was subcloned into the XhoI and NotI 
restriction sites of the pHR-SIN lentiviral vector. For virus produc-
tion, 6 μg pHR-SIN-mApple-Lifeact-7 was transfected with 4 μg 
pMDG VSV-G (envelope plasmid) and 4 μg pCMV delta 8.9 (packag-
ing plasmid) into HEK293T cells (at 70% confluency) using TransIT 
transfection reagent (Mirrus) and cultured overnight. Supernatant 
was collected after 48 hours, centrifuged, and filtered through a 0.45 
μm filter before concentration with LentiX concentrating solution 
(Clontech, Takara). 107 CTLs were transduced with concentrated 
viral particles in the presence of 6 μg protamine sulfate (P4020-1G, 
MilliporeSigma) in 1 mL of T cell media and left for 4 hours at 37°C. 
CTLs were diluted to 106 cells/mL before stimulation at a 1:1 ratio 
with irradiated PBMCs in the presence of 1 μg/mL PHA.
To generate the EGFP-ARPC3 construct, mRNA was extracted 
from OT-I CTLs using an RNEasy Mini Kit (QIAGEN). OT-I cDNA was 
generated from this using the AccuScript High-Fidelity First Strand 
cDNA Synthesis Kit (Agilent). To create a crippled CMV promoter, the 
majority of the enhancer region was deleted from EGFP-N1 (Clon-
tech, Takara) using the restriction enzyme AatII (Thermo Fisher) to 
generate the plasmid delCMV-EGFP-N1 described in Watanabe and 
Mitchison (77). ARPC3 primers were used to amplify the coding region 
based on NCBI Reference Sequence NM_019824.4: forward, 5′-ATG-
CCGGCATACCACTCTTCTCTC-3′; and reverse, 5′-CTGCCCAG-
GCCCCGAAAGAC-3′ with XhoI and BamHI restriction sites added. 
The product was ligated into delCMV-EGFP-N1, and 5 μg of DNA was 
nucleofected with 5 μg mApple-Lifeact-7 using the P3 Primary Cell Kit 
(V4XP-3024, Lonza) following the manufacturer’s recommendation 
for the 4D nucleofector (Lonza).
Cytotoxicity assay. OT-I CTLs or hCTLs were resuspended in 
killing assay media (phenol red–free RPMI 1640 containing 2% 
FBS) and mixed at effector-to-target ratios shown with EL4 (pulsed 
with 1 μM OVA257–264 for 1 hour at 37°C) or P815 (mixed with 0.5 μg/
mL mouse anti-human CD3 (clone UCHT1, catalog 555330, BD 
Pharmingen), respectively. For experiments with CK666 or CK689, 
OT-I CTLs were treated 10 minutes at 37°C with 90 μM of the drug, 
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For live cell imaging, 24 hours prior to imaging, OT-I CTLs were 
transfected with 2.5 μg of Lifeact-EGFP alone or with 2.5 μg of PACT-
mRFP (79) using Mouse T cell Nucleofector Kit (Lonza). Blue EL4 
target cells were pulsed with 1 μM OVA peptide for 1 hour at 37°C and 
washed twice in serum-free DMEM. For hCTLs, blue P815 target cells 
were washed twice in serum-free DMEM and incubated with anti-CD3 
antibody for 10 minutes at 37°C. Targets were plated on 35 mm glass- 
bottom culture dishes (P36G-1.5-14-C, MatTek) coated with 0.5 μg/mL 
ICAM-1/FC (796-IC-050, R&D Systems). Approximately 2 × 106 OT-I 
CTLs or hCTLs expressing fluorescent constructs in T cell media with 
25 mM HEPES (15630080, Thermo Fisher) were added dropwise to 
plated targets. For CK666 treatment, drug was added onto the dishes 
and kept during imaging. Interactions were imaged using a ×60 silicone 
objective (numerical aperture 1.3). Z-stacks with 0.8 μm intervals were 
imaged every 12 seconds. To measure speed of cell migration, EGFP- 
Lifeact expressing OT-I CTLs were pretreated for 10 minutes at 37°C 
with 90 μM CK666 or CK689 and drugs were kept during imaging. For 
each condition, images were taken every 10 seconds for 10 minutes with 
×20 objective (numerical aperture 0.75). To observe OT-I CTL migration 
behavior, Z-stacks with 1 μm intervals were taken at higher frequency 
(every 3 seconds for 5 minutes) using the ×60 silicone objective.
Images were obtained on an IX81 Olympus microscope equipped 
with an Andor Revolution system fitted with a CSU-X1 spinning-disk 
unit (Yogogawa), a 1024 × 1024 iXon Ultra EMCCD camera, a 2× 
camera adaptor (Andor Technology, Oxford Instruments), an environ-
mental chamber maintained at 37°C and 5% CO2 (Okolabs), and lasers 
exciting at 405 nm, 488 nm, 561 nm, and 633nm. All analyses were 
performed using Imaris software (Bitplane).
Super-resolution structured illumination microscopy. For super- 
resolution structured illumination microscopy (SR-SIM), coverslips 
(474030-9000-000, Zeiss) cleaned as previously described (80) 
were coated with 0.01% poly-l-lysine (MilliporeSigma) for 15 min-
utes, washed with PBS, and coated with 10 μg/mL hamster human-
ized anti-CD3 antibody (ChAgly, a gift from Herman Waldmann) or 
0.5 μg/mL ICAM-1 (796-IC-050, R&D) for 2 hours at 37°C. Coverslips 
were washed in D-PBS and equilibrated for 30 minutes with phenol 
red–free T cell media prior to addition of hCTLs (2 × 106 cells/mL). 
Cells were allowed to adhere for 12 minutes and subsequently fixed 
and stained as described in the Immunofluorescence and live cell imag-
ing section. Samples mounted in ProLong Gold (P36930, Thermo 
Fisher) were cured (48 hours at RT) and examined on a Zeiss ELYRA 
microscope (Cambridge), using a ×63 Plan Apochromat oil immersion 
objective (numerical aperture 1.4) and 405 nm, 488 nm, and 561 nm 
laser lines. Images were processed using Zen software (Zeiss) and 
visualized in Imaris.
Electron microscopy. P815 targets were washed and resuspended in 
serum-free media at 1 × 106 cells/mL. hCTLs at day 12 after stimula-
tion were preincubated for 5 hours with HRP (Boehringer Ingelheim) 
at 1 mg/mL directly added to medium to load endocytic compart-
ments, then washed, resuspended at 1 × 106 cells/mL in serum-free 
media, mixed 1:1 with the P815 targets in the presence of 1 μg/mL 
mouse anti-human CD3 antibody (clone UCHT1), and left 3 to 5 min-
utes in suspension before plating in 4-well Nunc plates and incubating 
at 37°C for 25 minutes to allow cell/cell interactions. Samples were 
fixed in 1.5% glutaraldehyde/2% paraformaldehyde, then washed and 
processed for DAB cytochemistry and EPON embedding as described 
previously (81). Samples were viewed on a FEI Tecnai G2 Spirit 
or 10,000 CD8+ cells (for degranulation assay) were recorded. Analy-
sis was performed using FlowJo 10 software.
Proliferation assay. Flat-bottom 96 well plates were prepared 
with or without anti-CD3 coating at 1 μg/mL (clone OKT3, catalog 
14-0037-82, eBioscience). hCTLs were stained with 10 μM cell pro-
liferation dye eFluor 450 (65-0842-85, Thermo Fisher) for 10 min-
utes in the dark at 37°C, followed by quenching with FBS-containing 
media for 5 minutes. Subsequently, hCTLs were washed 3× with 
FBS-containing media, and 20,000 hCTLs were seeded per well. 
After 5 days, cells were washed 2× in ice-cold D-PBS (Thermo Fisher) 
prior to staining with an anti–CD8-APC (clone SK1, catalog 344722, 
BioLegend) or anti-CD4-PE (clone A161A1, catalog 357404, BioLeg-
end) and Live/Dead fixable yellow (catalog L34959, Thermo Fisher). 
hCTLs were washed in PBS, 1% FCS prior to analysis on a LSR Fortes-
sa flow cytometer. Samples were gated on live CD8+ cells; results were 
analyzed using FlowJo 10 software.
Immunoblotting. CTLs were lysed in 50 mM Tris-HCl (pH 8), 150 
mM NaCl, 1 mM MgCl2 (M2670, MilliporeSigma), 2% Triton X-100 
(T8787, MilliporeSigma) buffer at a concentration of 2 × 107 cells/mL. 
For phospho-immunoblot prior to lysis, OT-I CTLs were pretreated for 
10 minutes at 37°C with 90 μM CK689 or CK666 in culture media and 
subsequently left untreated or stimulated with 50 nM of PMA (P8139, 
MilliporeSigma) or OVA257–264 (1 μM) for 15 minutes. hCTLs were stim-
ulated for 15 minutes at 37°C with 0.5 μg/mL or 1 μg/mL plate-bound 
anti-CD3 (clone OKT3, catalog 14-0037-82, eBioscience) before lysis. 
CTLs were lysed in phospho-lysis buffer (100 mM NaCl, 20 mM Tris-
HCL pH 7.4, 10% glycerol [G7893, MilliporeSigma], 1 mM EDTA, 
5 mM NaF [S7920, MilliporeSigma], 2 mM sodium orthovanadate 
[S6508, MilliporeSigma], 0.2% Triton X-100) supplemented with 
PhosSTOP (04906845001, Roche) and Protease Inhibitor Cocktail 
(04693132001, Roche). Lysates were loaded in 4× NuPage sample 
buffer (NP0007, Thermo Fisher) on a 4%–12% NuPage Bis-Tris Gel 
(NP0336, Thermo Fisher) under reducing conditions in MES Buffer 
(NP0002, Thermo Fisher), transferred to nitrocellulose membrane 
(10600003, GE Healthcare), and incubated with the indicated pri-
mary antibodies followed by goat anti-rabbit IgG (A16096, Thermo 
Fisher) or goat anti-mouse IgG (32430, Thermo Fisher) secondary 
antibody conjugated to HRP. Chemiluminescence was detected with 
ECL Prime kit (RPN2236, GE Healthcare) and recorded on a Chemi-
doc Imaging System (Bio-Rad). Quantitation of band intensity was 
performed using Image Lab 4.1 software (Bio-Rad). See complete 
unedited blots in the supplemental material.
Immunofluorescence and live cell imaging. OT-I CTLs or hCTLs 
were mixed at a 1:1 ratio in serum-free RPMI with OVA-pulsed EL4 
or P815 (mixed with 1μg/mL of human anti-CD3 (clone UCHT1, cata-
log Ab00112, Absolute Antibody), respectively, and incubated for 20 
to 40 minutes at 37°C. Cells were fixed for 15 minutes in 4% parafor-
maldehyde (15710-S, Electron Microscopy Systems) or 5 minutes in 
ice-cold methanol (10674862, Thermo Fisher), permeabilized in 0.1% 
Triton X-100, and blocked in 2% BSA in PBS (40 minutes). Samples 
were labeled overnight at 4°C with primary antibodies followed by 
fluorophore-conjugated secondary antibodies (1 hour at RT). Nuclei 
were stained for 5 minutes at RT with Hoechst 33342 (H3570, Thermo 
Fisher), and samples were mounted in ProLong Diamond Antifade 
Reagent (P36961, Thermo Fisher). Z-stack series of 0.4 μm intervals 
were taken with the ×60 oil objective (numerical aperture 1.42) or 
×100 oil objective (numerical aperture 1.45).
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lowing ethical review by the University of Cambridge Animal Welfare 
and Ethical Review Body (AWERB). Heparinized venous blood was 
collected from HDs and ARPC1B patient (18) after informed consent 
had been obtained. The study was approved by the Academic Medical 
Center Institutional Medical Ethics Committee in accordance with the 
1964 Declaration of Helsinki.
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BioTWIN transmission EM (Eindhoven) and images captured using a 
Gatan 4K US1000 CCD camera and FEI TIA software. Images were 
viewed in Adobe Photoshop CS6.
Image analysis and quantitation using IMARIS. For speed of migra-
tion measurement, the Spot detection module (size = 15 μm) was used 
to track moving cells. Nonadherent (floating) cells were excluded and 
5–11 cells were selected and subjected to the analysis tool to calculate 
their respective speed of migration.
With the series of confocal Z-stack acquired, CD8 staining was 
used to distinguish CTLs using the Surface tool, source channel: chan-
nel 2 = 488 with a surface detail of 0.5 μm. After threshold adjustment 
and background elimination, a mask was applied to channel 561 and 
channel 640 of CD8+ cells, prior to analysis using the colocalization 
tool. Results were expressed as a PCC where values between ± 0.50 
and ± 1 mean a high degree of colocalization, values between 0.30 and 
± 0.49 a moderate degree, and values below ± 0.29 a low degree. For 
intensity measurements, CD8+ cells identified by the surface tool were 
submitted to the analysis tool module, which computes the intensity 
mean in the third channel (corresponding to the 561 channel). Values 
were then plotted in GraphPad Prism.
For actin depletion measurements, the ×60 objective was posi-
tioned in the middle of the slide and 10 fields of view were success-
ively acquired from the left to the right end. The oblique slicer tool (with 
a depth of 1.23 μm) was applied at the interface between the CTLs con-
tacting a target to generate the en face view of the synapse. A snapshot of 
the synapse was taken and the intensity of actin quantified using ImageJ 
(NIH) as shown in Supplemental Figure 1. All CD8-positive cells and con-
jugates present in the field of view were identified and counted manually.
Statistics. GraphPad Prism was used to create all graphics and for 
statistical analysis. A 2-tailed Student’s t test was used where indicated 
to compare mean values. P < 0.05 was considered significant.
Study approval. This research was regulated under the Animals 
(Scientific Procedures) Act 1986 Amendment Regulations 2012 fol-
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